Bright Minds Biosciences Inc (DRUG) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bright Minds Biosciences Inc   (NASDAQ: DRUG)


Bright Minds Biosciences Inc 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Bright Minds Biosciences Inc 's ROA in the fourth quarter of 2025?
Bright Minds Biosciences Inc recorded a cumulative net loss of $-9 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -14.49%.

However, within the Healthcare sector 329 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4196.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Sep 30 2024)
IV. Quarter
Y / Y Total Assets Change 1282.92 % 1282.92 % 1282.92 % 1282.92 % -11.26 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -9 -2 -2 -2 -2
Return On Assets (TTM) -14.49 % -4.32 % -6.19 % -10.91 % -45.9 %
DRUG's Total Ranking # 4196 # # # # 4952
Total Assets (TTM) in million 65 65 65 65 5
Seq. Total Assets Change 0 % 0 % 0 % 1282.92 % 0 %
Seq. Net Income Change - - - - -

DRUG's 5 Years Annual ROA >> Back to DRUG Management Effectiveness >> Compare DRUG ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 116
Sector # 330
Overall # 3493

Return On Assets Statistics
High Average Low
-14.49 %
-72.84 %
-123.81 %
(Sep 30 2025)   (Sep 30 2022)





Financial Statements
Bright Minds Biosciences Inc 's Assets $ 65 million DRUG's Balance sheet
Bright Minds Biosciences Inc 's Income $ -9 million Quarterly DRUG's Income Statement
DRUG's Income by Division See DRUG's Income by Division



Annual Return On Assets (Sep 30 2025)
FY 2025		 (Sep 30 2024)
FY 2024		 (Sep 30 2023)
FY 2023		 (Sep 30 2022)
FY 2022		 (Sep 30 2020)
FY 2021
Y / Y Total Assets Change 1282.92 % -11.26 % -43.09 % 1301.39 % -
Total Assets in million 65 5 5 9 1
Y / Y Net Income Change - - - - -
Net Income in million -9 -2 -6 -11 0
Annual Return On Assets -14.49 % -45.9 % -107.17 % -123.81 % -54.06 %

DRUG's 5 Years Annual ROA >> Back to DRUG Management Effectiveness >> Compare DRUG ROA to its Competitors



More Return On Assets Ratios
DRUG's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DRUG's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DRUG's Competitors
Subscribers only: Roa for Bright Minds Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for DRUG's Customers

You may also want to know
DRUG's Roi DRUG's Inventory Turnover Ratio DRUG's Growth Rates DRUG's Dividend Comparisons
DRUG's Profitability Ratios DRUG's Asset Turnover Ratio DRUG's Dividend Growth
DRUG's Roe DRUG's Valuation Ratios DRUG's Financial Strength Ratios DRUG's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector ROA

Date modified: 2026-07-07T10:24:00+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.